Scrambler therapy for established chemotherapy-induced peripheral neuropathy

MS-N130 · Supportive care · Human evidence · Appraised 25 October 2026

Can Scrambler therapy reduce pain, tingling or numbness from established chemotherapy-induced peripheral neuropathy (CIPN)?

Evidence at a glance

Evidence label: Promising but unconfirmed; small device trials do not establish routine benefit
Benefit: A small randomized phase II pilot favored Scrambler therapy over TENS for several patient-reported symptoms, but sham-controlled evidence is limited.
Certainty: Low because trials are small, blinding is difficult, outcomes are subjective and protocols and comparators vary.
Risk: Reported harms are generally mild, but device placement and electrical stimulation require trained screening, especially with implanted devices, broken skin or altered sensation.

What was studied

Population and design: A randomized phase II pilot assigned 50 people with CIPN to Scrambler therapy or transcutaneous electrical nerve stimulation (TENS) for two weeks; 46 were evaluable. A separate small sham-controlled pilot tested ten 30-minute sessions.

Studied regimen: Electrodes are placed on intact skin outside the painful area to deliver changing electrical signals. This is a clinic-delivered electroanalgesia protocol, not a home TENS prescription and not anticancer therapy.

What the evidence found

In the phase II pilot, the proportion reporting at least 50% improvement in pain, tingling or numbness ranged from 36% to 56% with Scrambler therapy and 16% to 28% with TENS across symptoms. The study was designed to generate a signal, not a definitive effect estimate.

The sham-controlled pilot and crossover report add uncertainty because samples were small. A 2026 review judged the overall CIPN evidence encouraging but still limited by heterogeneity and risk of bias. Minimal treatment-related toxicity has generally been reported.

How to interpret it

These results justify discussion or a clinical trial where an experienced service exists, but they do not establish Scrambler therapy as a proven standard. Natural recovery, attention effects and regression to the mean can be large in pain studies. This treatment has not been shown to repair nerves, prevent chemotherapy dose changes or improve cancer outcomes.

Practical safety context

Do not place electrodes over broken, infected, irradiated or insensate skin. Ask about pacemakers, defibrillators, seizure history and other electrical-device restrictions. Worsening weakness, falls or asymmetric neurologic signs need evaluation rather than repeated symptom treatment.

Questions for the care team

Is the neuropathy definitely chemotherapy-related, or could diabetes, vitamin deficiency, spinal disease or another cause contribute?
What is the service’s protocol, training and sham-controlled evidence?
How will pain, numbness, function and treatment burden be measured separately?

Funding and conflicts

The pivotal comparison was a small phase II pilot; full-text funding and conflict details were not verified in this abstract-level appraisal. Device studies can be vulnerable to operator and expectation effects.

Sources

Last literature search: 25 October 2026. Record appraisal: 25 October 2026. This page is educational and does not replace individualized medical advice. Symptom or function improvement must not be interpreted as evidence of tumor response, delayed recurrence or longer survival.